StockData
Merck & Co., Inc. logo

Merck & Co., Inc.

MRKNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 7, 2026Score 9/30242% above fair value
$148.36−1.16 (-0.78%)

Close on Nov 2, 2026Market cap $366.03BP/E 118.7Yield 2.21%

Merck Lenvima (lenvatinib by Quarter

Lenvima (lenvatinib — Eisai oncology alliance revenue) — Worldwide reported growth YoY (%) (%)

QuarterlyAnnual

Merck Lenvima (lenvatinib: 7.0% in Q2 2026, up 1.0 pts from a year earlier.

Latest, Q2 2026
7.0%
Period ended Jun 30, 2026
Change on a year earlier
+1.0 pts
6.0% in Q2 2025
History
27 quarters
Since Q2 2019
Sources
27
Documents cited below

Where the Q2 2026 figure comes from

“|| Alliance Revenue – Lenvima (2) | 283 | 265 | 7 | 194 | 183 | 6 | 90 | 83 | 8”

Source: Form 8-K (tm2621496d1_ex99-1.htm, filed 2026-08-04) ↗

Reported in Form 8-K Table 3 / 3a / 3b Product Sales.

Quarterly history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedLenvima (lenvatinib — Eisai oncology alliance revenue) — Worldwide reported growth YoY (%) (%)Year on yearSource
Q2 2026Jun 30, 20267.0%+1.0 ptsForm 8-K (tm2621496d1_ex99-1.htm, filed 2026-08-04) ↗
Q4 2025Dec 31, 20257.0%-6.0 ptsForm 8-K (tm264564d1_ex99-1.htm, filed 2026-02-03) ↗
Q3 2025Sep 30, 20253.0%+6.0 ptsForm 8-K (tm2529620d1_ex99-1.htm, filed 2025-10-30) ↗
Q2 2025Jun 30, 20256.0%+3.0 ptsForm 8-K (tm2521736d1_ex99-1.htm, filed 2025-07-29) ↗
Q1 2025Mar 31, 20251.0%-9.0 ptsForm 8-K (tm2512885d1_ex99-1.htm, filed 2025-04-24) ↗
Q4 2024Dec 31, 202413.0%+8.0 ptsForm 8-K (tm255059d1_ex99-1.htm, filed 2025-02-04) ↗
Q3 2024Sep 30, 2024-3.0%-32.0 ptsForm 8-K (tm2426878d1_ex99-1.htm, filed 2024-10-31) ↗
Q2 2024Jun 30, 20243.0%-2.0 ptsForm 8-K (tm2420272d1_ex99-1.htm, filed 2024-07-30) ↗
Q1 2024Mar 31, 202410.0%+8.0 ptsForm 8-K (tm2412490d1_ex99-1.htm, filed 2024-04-25) ↗
Q4 2023Dec 31, 20235.0%–Form 8-K (tm244517d1_ex99-1.htm, filed 2024-02-01) ↗
Q3 2023Sep 30, 202329.0%+22.0 ptsForm 8-K (tm2328962d1_ex99-1.htm, filed 2023-10-26) ↗
Q2 2023Jun 30, 20235.0%-23.0 ptsForm 8-K (tm2322190d1_ex99-1.htm, filed 2023-08-01) ↗
Q1 2023Mar 31, 20232.0%-73.0 ptsForm 8-K (tm2313695d1_ex99-1.htm, filed 2023-04-27) ↗
Q3 2022Sep 30, 20227.0%-25.0 ptsForm 8-K (tm2227726d1_ex99-1.htm, filed 2022-10-27) ↗
Q2 2022Jun 30, 202228.0%+9.0 ptsForm 8-K (tm2221828d1_ex99-1.htm, filed 2022-07-28) ↗
Q1 2022Mar 31, 202275.0%+74.0 ptsForm 8-K (tm2213615d1_ex99-1.htm, filed 2022-04-28) ↗

Cite this data

StockData. (2026). Merck Lenvima (lenvatinib (%), quarterly Q2 2019–Q2 2026 [Data set]. Compiled from Merck SEC filings and investor materials. https://stockdatahq.com/stocks/mrk/kpis/rev-lenvima-ww-nom-yoy

See every metric in the Merck KPI table. Data updated Oct 26, 2026.